올리고뉴클레오티드 합성 시장 : 제품 유형, 합성 규모, 제공 방법, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Oligonucleotide Synthesis Market is projected to grow by USD 31.69 billion at a CAGR of 17.43% by 2032.

Oligonucleotide synthesis is a core enabling technology for precision medicine, molecular diagnostics, synthetic biology, and genomic research. The field covers custom DNA and RNA oligos, antisense oligonucleotides, siRNA, aptamers, CRISPR guide RNAs, primers, probes, and modified nucleic acids produced primarily through solid-phase phosphoramidite chemistry.

Demand is supported by FDA-cleared molecular tests, expanding genomic sequencing workflows, and approved RNA-targeted therapies such as nusinersen, patisiran, givosiran, inclisiran, and tofersen. As therapeutic pipelines mature, buyers increasingly evaluate oligonucleotide synthesis providers on GMP capacity, analytical quality, modification breadth, delivery expertise, regulatory documentation, and supply-chain reliability.

Transformative Shifts in the Oligonucleotide Landscape

The oligonucleotide synthesis landscape is shifting from research-scale custom orders toward clinical and commercial manufacturing. Therapeutic oligos require stringent control of sequence fidelity, impurity profiles, endotoxin, residual solvents, and identity testing by methods such as LC-MS, HPLC, capillary electrophoresis, and NMR.

Manufacturers are investing in higher-throughput synthesizers, greener solvent strategies, automation, closed processing, and integrated CDMO services. At the same time, demand for complex chemistries, including 2'-O-methyl, 2'-MOE, phosphorothioate backbones, LNA, GalNAc conjugates, and chemically modified siRNA, is raising technical requirements and quality expectations across the value chain.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is improving oligonucleotide discovery and manufacturing by accelerating sequence selection, off-target screening, secondary-structure prediction, immunogenicity assessment, and manufacturability evaluation. AI-enabled models are increasingly used with public genomic databases, RNA expression datasets, and high-throughput screening outputs to prioritize candidates before costly wet-lab validation.

In production, machine learning can support real-time process monitoring, predictive maintenance, chromatographic method development, and deviation detection. The strongest near-term value is not replacing validated chemistry, but reducing cycle times, improving batch consistency, strengthening quality-by-design workflows, and helping quality teams interpret complex analytical datasets.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific is gaining importance as China, India, Japan, South Korea, and Australia expand genomics, vaccine, and biopharmaceutical capacity. China offers scale, domestic biotech demand, and active nucleic acid research; India contributes cost-competitive manufacturing, clinical research services, and expanding diagnostics infrastructure; Japan maintains advanced nucleic acid science and high-quality pharmaceutical standards; while South Korea and Australia support translational medicine, clinical studies, and public-health genomics ecosystems.

North America remains a leading innovation center because of U.S. FDA experience with RNA-targeted drugs, NIH-funded genomics research, venture-backed biotechnology clusters, and established GMP CDMO infrastructure, with Canada contributing genomics, academic medicine, and clinical translation. Europe is strong in regulatory science, academic translation, and quality manufacturing, supported by EMA oversight and coordinated research programs. Latin America is developing demand through molecular diagnostics, infectious-disease surveillance, and clinical research activity, led by Brazil and Mexico. The Middle East is advancing national genomics, precision medicine, and hospital-based sequencing programs, particularly in Gulf states. Africa is building capacity through public-health sequencing, pathogen surveillance, newborn screening initiatives, and regional laboratory networks, creating a foundation for future oligonucleotide demand.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN demand is led by Singapore's biomedical hub and growing diagnostics adoption across Malaysia, Thailand, Indonesia, Vietnam, and the Philippines, where infectious-disease testing, academic genomics, and clinical research are increasing the need for primers, probes, and sequencing reagents. The GCC is advancing national genomics and precision medicine programs in Saudi Arabia, the United Arab Emirates, Qatar, and neighboring states, supporting demand for sequencing reagents, synthetic oligos, probes, and clinical research tools.

The European Union benefits from harmonized pharmaceutical regulation, Horizon Europe research funding, cross-border health-data initiatives, and strong GMP expectations. BRICS economies provide population scale, manufacturing depth, expanding healthcare access, and growing biotechnology capabilities, with China and India particularly relevant to oligonucleotide production and research supply chains. G7 countries concentrate advanced therapeutic development, regulatory maturity, public biomedical funding, and early adoption of RNA-targeted medicines. NATO members increasingly view biosecurity, resilient supply chains, pathogen surveillance, and dual-use biotechnology governance as strategic priorities, reinforcing the importance of secure oligonucleotide sourcing and quality-controlled nucleic acid manufacturing.

Key Country Insights Across Major Oligonucleotide Markets

The United States leads therapeutic oligonucleotide commercialization through FDA approvals, biotech financing, academic research, and specialized GMP manufacturing, while Canada contributes genomics research, hospital-based innovation, and clinical translation. Mexico and Brazil represent important Latin American demand centers for molecular diagnostics, public-health laboratories, infectious-disease surveillance, and contract research, with Brazil also supported by a large academic and biomedical research base.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong academic science, hospital research networks, clinical trial infrastructure, and regulated biomanufacturing, with Germany and France maintaining deep pharmaceutical and analytical capabilities and the United Kingdom supporting genomics-driven clinical adoption. Russia maintains domestic life-science and pharmaceutical capabilities under constrained international supply conditions, increasing emphasis on localized sourcing and research continuity. In Asia-Pacific, China, India, Japan, Australia, and South Korea are critical markets: China and India are scaling production, research services, and diagnostics capacity; Japan emphasizes innovation, quality, and advanced nucleic acid science; South Korea is expanding biopharmaceutical manufacturing and translational medicine; and Australia supports clinical research, population genomics, and public-health sequencing programs.

Actionable Recommendations for Industry Leaders

Industry leaders should align capacity with the shift from discovery oligos to GMP therapeutic production. Priority investments include validated solid-phase synthesis platforms, high-resolution purification, mass spectrometry, impurity characterization, electronic batch records, data integrity controls, and robust supplier qualification for amidites, controlled-pore glass, enzymes, solvents, and specialty reagents.

Commercial teams should segment customers by research, diagnostic, and therapeutic use cases. Winning providers will combine rapid custom synthesis, regulatory documentation, scalable tech transfer, secure data handling, and expertise in modified RNA, antisense chemistry, siRNA, CRISPR guide RNA, aptamers, probes, and conjugation technologies. Leaders should also strengthen regional redundancy, establish quality agreements early, and integrate AI-enabled design tools with validated laboratory workflows.

Research Methodology

This executive summary is based on secondary research from regulatory databases, peer-reviewed literature, clinical trial registries, government research programs, pharmacopeial references, and recognized industry standards for pharmaceutical quality systems. Insights were cross-checked against known FDA and EMA precedents for oligonucleotide therapeutics, documented genomics initiatives, and established nucleic acid analytical practices.

The analysis evaluates technology drivers, manufacturing shifts, regional adoption patterns, regulatory considerations, and competitive priorities. It emphasizes verifiable evidence, including approved therapeutic modalities, public biomedical programs, validated chemistry platforms, and documented quality requirements, while avoiding unsupported projections, vendor claims, market estimation, market sizing, market share, or forecasting.

Conclusion

Oligonucleotide synthesis is moving from a specialized research service into a strategic manufacturing platform for precision therapeutics, molecular diagnostics, and genomic innovation. Scientific validation from approved RNA-targeted medicines has strengthened confidence in antisense, siRNA, and other nucleic acid modalities, while molecular testing and sequencing workflows continue to expand practical use cases.

Future competitiveness will depend on quality systems, manufacturing scale, chemistry expertise, data-driven development, regulatory readiness, and regional supply resilience. Organizations that integrate AI-enabled design, GMP readiness, analytical rigor, secure data practices, and customer-specific technical support will be best positioned to meet the evolving requirements of oligonucleotide synthesis.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Oligonucleotide Synthesis Market, by Product Type

• 7.1. Equipment/Instruments
  • 7.1.1. DNA/RNA Synthesizers
  • 7.1.2. Microarray Synthesizers
• 7.2. Reagents & Consumables
  • 7.2.1. Enzymes
  • 7.2.2. Labeling Reagents
  • 7.2.3. Purification Reagents
  • 7.2.4. Synthesis Reagents
• 7.3. Software & Services
  • 7.3.1. Bioinformatics Tools
  • 7.3.2. Cloud Storage & Management Solution
  • 7.3.3. Custom Oligo Synthesis Services
  • 7.3.4. Data Analysis Platforms
• 7.4. Synthesized Oligonucleotides
  • 7.4.1. DNA Oligonucleotides
  • 7.4.2. RNA Oligonucleotides

8. Oligonucleotide Synthesis Market, by Synthesis Scale

• 8.1. Custom Oligonucleotide Synthesis
• 8.2. Large-Scale/Commercial Manufacturing

9. Oligonucleotide Synthesis Market, by Delivery Method

• 9.1. Enzymatic Synthesis
• 9.2. Solid-Phase Synthesis

10. Oligonucleotide Synthesis Market, by Application

• 10.1. Diagnostics
  • 10.1.1. Biosensors
  • 10.1.2. Molecular Imaging
  • 10.1.3. PCR & Sequencing
• 10.2. Drug Discovery & Development
  • 10.2.1. Lead Optimization
  • 10.2.2. Target Validation
• 10.3. Research
  • 10.3.1. Functional Genomics
  • 10.3.2. Gene Expression Analysis
  • 10.3.3. Gene Synthesis
• 10.4. Therapeutics
  • 10.4.1. Antisense Therapy
  • 10.4.2. CRISPR-Based Therapeutics
  • 10.4.3. RNA Interference

11. Oligonucleotide Synthesis Market, by End-User

• 11.1. Academic & Research Institutes
• 11.2. Contract Research Organizations
• 11.3. Diagnostic Laboratories
• 11.4. Pharmaceutical & Biotechnology Companies

12. Oligonucleotide Synthesis Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Oligonucleotide Synthesis Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Oligonucleotide Synthesis Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Agilent Technologies, Inc.
• 16.2. Ajinomoto Bio-Pharma Services
• 16.3. Bio-synthesis Inc.
• 16.4. Biocomma Ltd.
• 16.5. Biolegio B.V.
• 16.6. Biolytic Lab Performance Inc.
• 16.7. Bon Opus Biosciences, LLC
• 16.8. Creative Biogene
• 16.9. Cusabio Technology LLC
• 16.10. Danaher Corporation
• 16.11. Eurofins Genomics LLC
• 16.12. Eurogentec S.A. by Kaneka Corporation
• 16.13. GE HealthCare Technologies Inc.
• 16.14. Generi Biotech
• 16.15. Genscript Corporation
• 16.16. Hongene Biotech Corp.
• 16.17. LGC Genomics Limited
• 16.18. Maravai Intermediate Holdings, LLC
• 16.19. Merck KGaA
• 16.20. Microsynth AG
• 16.21. Nitto Denko Avecia Inc.
• 16.22. Novartis AG
• 16.23. PerkinElmer, Inc.
• 16.24. REPROCELL Inc.
• 16.25. Synbio Technologies
• 16.26. TAG Copenhagen A/S
• 16.27. TCI Chemicals Pvt. Ltd.
• 16.28. Thermo Fisher Scientific Inc.